Frontiers in CAR-T cell therapy for autoimmune diseases

Li, Yan-Ruide; Lyu, Zibai; Chen, Yuning; Fang, Ying; Yang, Lili

doi:10.1016/j.tips.2024.07.005

Trends in Pharmacological Sciences

2024

DOI: 10.1016/j.tips.2024.07.005

|View full text |Cite

Frontiers in CAR-T cell therapy for autoimmune diseases

Yan-Ruide Li,

Zibai Lyu,

Yuning Chen

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 103 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Chimeric antigen receptor T-cell therapy in autoimmune diseases

Liu,

Zhao,

Zhao

2024

Front. Immunol.

View full text Add to dashboard Cite

The administration of T cells that have been modified to carry chimeric antigen receptors (CARs) aimed at B cells has been an effective strategy in treating B cell malignancies. This breakthrough has spurred the creation of CAR T cells intended to specifically reduce or alter the faulty immune responses associated with autoimmune disorders. Early positive outcomes from clinical trials involving CAR T cells that target the B cell protein CD19 in patients suffering from autoimmune diseases driven by B cells have been reported. Additional strategies are being developed to broaden the use of CAR T cell therapy and enhance its safety in autoimmune conditions. These include employing chimeric autoantireceptors (CAAR) to specifically eliminate B cells that are reactive to autoantigens, and using regulatory T cells (Tregs) engineered to carry antigen-specific CARs for precise immune modulation. This discussion emphasizes key factors such as choosing the right target cell groups, designing CAR constructs, defining tolerable side effects, and achieving a lasting immune modification, all of which are critical for safely integrating CAR T cell therapy in treating autoimmune diseases.

show abstract

Chimeric antigen receptor T-cell therapy in autoimmune diseases

Liu,

Zhao,

Zhao

2024

Front. Immunol.

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Frontiers in CAR-T cell therapy for autoimmune diseases

Cited by 1 publication

References 103 publications

Chimeric antigen receptor T-cell therapy in autoimmune diseases

Chimeric antigen receptor T-cell therapy in autoimmune diseases

Contact Info

Product

Resources

About